Is Augmentin (amoxicillin-clavulanate) effective for treating Escherichia coli (E. coli) urinary tract infections (UTI) in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Augmentin for E. coli UTI in Pediatric Patients

Augmentin (amoxicillin-clavulanate) is effective for treating E. coli urinary tract infections in pediatric patients and should be considered as a first-line oral antibiotic option, particularly for complicated or resistant infections. 1, 2

Efficacy for E. coli UTI

  • Augmentin is particularly effective for treating urinary tract infections because the clavulanic acid component reduces resistance in most Gram-negative urinary pathogens, including E. coli 1
  • Studies show success rates of approximately 70% even for amoxicillin-resistant organisms 1
  • For E. coli specifically, treatment success depends on both the duration of therapy and bacterial virulence factors 2

Treatment Recommendations

  • Dosing: The recommended dosage is 20 mg/kg/day of amoxicillin and 5 mg/kg/day of clavulanic acid in three divided doses 2
  • Duration: A 10-day course is significantly more effective than a 3-day course for pediatric UTIs (82% vs 55% success rate) 2
  • For acute UTIs in children, oral antibiotics are the typical treatment approach 3

Factors Affecting Treatment Success

  • Bacterial factors: E. coli strains that are adhesin-positive have lower cure rates (56%) compared to adhesin-negative strains (100% cure rate regardless of treatment duration) 2
  • Host factors: The presence of vesicoureteral reflux (VUR) can affect treatment outcomes, with higher failure rates observed in patients with reflux 2
  • Age considerations: Neonates with UTI require special consideration due to higher incidence of urinary anomalies and concomitant bacteremia 3

When to Consider Augmentin

  • Particularly valuable for treating UTIs caused by multiply resistant bacteria 1
  • Can be effective against extended-spectrum beta-lactamase-producing E. coli (ESBL-EC) when combined with certain cephalosporins 4
  • Should be considered when local resistance patterns show high rates of resistance to first-line agents 3

Monitoring and Follow-up

  • Regular follow-up with imaging studies (ultrasound) and monitoring of the child's height, weight, blood pressure, and possibly serum creatinine are recommended 3
  • The main purposes of treating UTIs are to cure acute infection and prevent recurrent UTIs and renal scarring 3
  • Approximately 15% of children may develop evidence of renal scarring after the first episode of UTI 3

Potential Pitfalls and Considerations

  • Gastrointestinal side effects are minimal at standard dosing 1
  • For complicated UTIs or those with poor response to antibiotics within 48 hours, additional imaging and possibly different antimicrobial strategies should be considered 3
  • In cases of recurrent UTIs, evaluation for underlying abnormalities such as VUR is warranted 3
  • For children with breakthrough infections despite prophylaxis, intervention beyond antimicrobial therapy should be considered 3

Special Populations

  • For neonates and infants under 2 months, more conservative management may be needed due to higher incidence of sepsis and renal anomalies 3
  • In children with E. coli O104:H4 (which can cause hemolytic uremic syndrome), regular follow-up visits are recommended even after successful treatment of the UTI 5

References

Research

The role of bacterial adhesins in the outcome of childhood urinary tract infections.

American journal of diseases of children (1960), 1993

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.